Australian pharma cos looking for joint-ventures over the next 2 years - PWC survey

23 September 2015

Several pharmaceutical companies in Australia have indicated they will be looking for strategic alliances and joint ventures in the next two years, which could create opportunities for Australian biotechs, according to a 2015 PriceWaterhouseCoopers (PWC) survey of the Australian medicines industry.

Medicines Australia chief executive Tim James said: “The innovative, research-based medicines industry can play a key role in delivering a smarter, stronger, healthier Australia.”

The collaboration and investment could bring enormous benefits to the Australian economy, said Tim James. However, in order to achieve this, the policy-makers will need to help create the conditions that will attract investment, growth and job creation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK